newsfilter
← Latest News
GlobeNewswire·

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third